ANVS
Annovis Bio, Inc.
There isn't enough reported data to score ANVS yet.
ANVS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Healthy |
ANVS's balance sheet is currently healthy, but its profitability is under pressure. There isn't enough data to rate its revenue and cash flow.
ANVS PE Valuation
ANVS has no meaningful PE right now: it lost money over the past year.
ANVS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect ANVS's losses to shrink, with revenue holding steady.
ANVS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.79 | +$0.28 |
| Q1 2026 | -$1.71 | +$0.48 |
| Q4 2025 | -$1.40 | +$1.19 |
| Q3 2025 | -$1.47 | +$3.00 |
| Q2 2025 | -$2.07 | +$3.06 |
| Q1 2025 | -$2.19 | +$3.57 |
| Q4 2024 | -$2.59 | +$3.64 |
| Q3 2024 | -$4.47 | +$0.36 |
ANVS is still losing money, but far less than before: $1.79 per share over the past year, against $6.23 at its worst in late 2023.
ANVS Quarterly Revenue
ANVS's revenue is shrinking: $0 last quarter.
ANVS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$21.9M | -$16.8M |
| Q1 2026 | -$9M | -$912.5K |
| Q4 2025 | -$8.9M | -$641.7K |
| Q3 2025 | -$3.5M | -$286.3K |
| Q2 2025 | -$5.1M | -$1.7M |
| Q1 2025 | -$8.1M | -$1.1M |
| Q4 2024 | -$8.3M | +$1.1M |
| Q3 2024 | -$3.2M | +$6.2M |
ANVS has burned cash in almost every quarter: −$43M over the past year, against −$25M the year before.
ANVS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +35% | +9.7M shares |
| 1 year | +115% | +20.1M shares |
| 3 years | +360% | +29.4M shares |
| 5 years | +495% | +31.2M shares |
| Available history | +450% | +30.7M shares |
ANVS has 38M diluted shares, up 115% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
| Q3 2019 | — |
ANVS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2019 | 1.9x | Healthy |
ANVS's net debt is about 1.9 years of its operating earnings (EBITDA).
ANVS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.8 | Neutral |
| Stochastic | 17.9 | Oversold |
ANVS's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
ANVS PE vs Healthcare Sector
ANVS has no meaningful PE right now: it lost money over the past year.
ANVS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.06 | 20% below |
| 20 week MA | $1.42 | 40% below |
| 50 week MA | $2.10 | 60% below |
| 100 week MA | $2.37 | 64% below |
| 200 week MA | $6.67 | 87% below |
ANVS is in a downtrend: it's below all five of its weekly moving averages, and 87% below its 200-week average.
ANVS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.52 | $6.55 | +0.5% |
| 2021 | $6.55 | $20.7 | +215% |
| 2022 | $20.7 | $13.1 | -36% |
| 2023 | $13.1 | $18.7 | +42% |
| 2024 | $18.7 | $5.27 | -72% |
| 2025 | $5.27 | $3.60 | -32% |
| 2026 YTD | $3.60 | $0.85 | -76% |
ANVS's yearly returns have swung widely, from +215% in 2021 to −72% in 2024. It's down 76% so far in 2026.